Health Catalyst (HCAT) to Release Earnings on Wednesday

Health Catalyst (NASDAQ:HCAT) is expected to be posting its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of $0.10 per share and revenue of $73.9880 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:00 PM ET.

Health Catalyst Price Performance

Shares of Health Catalyst stock opened at $1.73 on Wednesday. The stock has a market cap of $122.36 million, a P/E ratio of -1.09 and a beta of 1.73. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.88 and a current ratio of 1.88. The stock’s fifty day moving average is $2.28 and its 200 day moving average is $2.74. Health Catalyst has a one year low of $1.72 and a one year high of $5.56.

Insider Buying and Selling at Health Catalyst

In other Health Catalyst news, Director Julie Larson-Green sold 47,997 shares of the stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $2.67, for a total transaction of $128,151.99. Following the completion of the transaction, the director owned 73,573 shares of the company’s stock, valued at $196,439.91. This represents a 39.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Benjamin Landry sold 27,425 shares of Health Catalyst stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $2.64, for a total value of $72,402.00. Following the completion of the sale, the general counsel directly owned 100,000 shares in the company, valued at $264,000. This trade represents a 21.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 2.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of HCAT. AQR Capital Management LLC raised its stake in Health Catalyst by 816.8% during the first quarter. AQR Capital Management LLC now owns 168,344 shares of the company’s stock valued at $763,000 after purchasing an additional 149,981 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Health Catalyst by 7.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,047 shares of the company’s stock worth $163,000 after buying an additional 2,624 shares during the last quarter. Focus Partners Wealth purchased a new stake in shares of Health Catalyst during the 1st quarter valued at about $46,000. Geode Capital Management LLC lifted its holdings in shares of Health Catalyst by 11.4% in the 2nd quarter. Geode Capital Management LLC now owns 1,662,455 shares of the company’s stock valued at $6,269,000 after acquiring an additional 169,580 shares during the last quarter. Finally, Rhumbline Advisers lifted its holdings in shares of Health Catalyst by 13.5% in the 2nd quarter. Rhumbline Advisers now owns 101,986 shares of the company’s stock valued at $384,000 after acquiring an additional 12,127 shares during the last quarter. 85.00% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

HCAT has been the topic of a number of analyst reports. Wells Fargo & Company lowered their price objective on Health Catalyst from $6.00 to $5.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 11th. UBS Group reaffirmed an “outperform” rating on shares of Health Catalyst in a report on Tuesday, November 11th. Stifel Nicolaus reduced their price objective on shares of Health Catalyst from $4.50 to $3.75 and set a “hold” rating for the company in a research note on Tuesday, November 11th. William Blair restated an “outperform” rating on shares of Health Catalyst in a research report on Tuesday, November 11th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Health Catalyst in a report on Monday, December 29th. Five investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $4.32.

Health Catalyst Company Profile

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.